1. Barry M, Tilson L. Recent developments in pricing and reimbursement of medicines in Ireland. Expert Rev Pharmacoecon Outcomes Res. 2007;7:605–611.
2. Brazier JE, Roberts J. Estimating a preference-based index from the SF-12. Med Care. 2004;42:851–859.
3. Campbell MK, Elbourne DR, Altman DG, et al. CONSORT statement: Extension to cluster randomised trials. BMJ. 2004;328:702–708.
5. Central Statistics Office. Dublin (www.cso.ie). (Accessed June 2008)
6. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: Secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005;143:659–672.
7. Cupples ME, Byrne MC, Smith SM, Leathem C, Murphy AW. Secondary prevention of cardiovascular disease in different primary healthcare systems, with and without pay-for-performance. Heart. 2008;94:1594–1600.
8. D'Agostino RB, Russell M, Huse DM, et al. Primary and subsequent coronary risk appraisal: New results from The Framingham Study. Am Heart J. 2000;139:272–281.
9. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601–1610.
10. Department of Health and Children. The National Heartwatch Programme: Clinical report - March 2003 to December 2005. Dublin; 2006.
11. Drummond MF, Sculpher MJ, Torrance GW, O'Brien J, Stoddart GL. Methods for the economic evaluation of health care programmes. New York: Oxford University Press;2005.
12. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. New York: Oxford University Press; 2007.
13. Hardin JW, Hilbe JM. Generalised estimating equations. London: Chapman and Hall/CRC Press; 2003.
14. Johnston K, Gray A, Moher M, et al. Reporting the cost-effectiveness of interventions with nonsignificant effect differences: Example from the a trial of secondary prevention of heart disease. Int J Technol Assess Health Care. 2003;19:476–489.
15. Ketola E, Laatikainen T, Vartianinen E. Evaluating risk for cardiovascular diseases -vain or value? How do different cardiovascular risk scores act in real life. Eur J Public Health. 2010;20:107–112.
16. Lacey EA, Walters SJ. Continuing inequality: Gender and social class influences on self perceived health after a heart attack. J Epidemiol Community Health. 2003;57:622–627.
17. Manca A, Hawkins N, Sculpher M. Estimating mean QALYs in trial based cost effectiveness analysis: The importance of controlling for baseline utility. Health Econ. 2005;14:487–496.
18. Murphy AW, Cupples ME, Smith S, et al. Secondary prevention of heart disease in general practice: A cluster randomised controlled trial of tailored practice and patient care plans. BMJ. 2009;339:b4220.
19. Netten A, Curtis J. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit. University of Kent; 2006.
21. O'Neill C, Normand C, Cupples M, McKnight A. Cost effectiveness of personal health education in primary care for people with angina in the Greater Belfast area of Northern Ireland. J Epidemiol Community Health. 1996;50:538–540.
22. Raftery JP, Yao GL, Murchie P, Campbell NC, Ritchie LD. Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: Follow up of a randomised controlled trial. BMJ. 2005;330:707.
23. Robinson M, Palmer S, Sculpher M, et al. Cost effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: Systematic review and decision-analytical modelling. Health Technol Assess. 2005;9:iii-iv, ix-xi, 1–158.
24. Turner DA, Paul SK, Stone M, et al. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care. Heart. 2008;94:1601–1606.
25. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233.